Brendan discusses the transformative potential of CRISPR in research and medicine, highlighting ongoing challenges that are being addressed. He also emphasizes the rapid advancements in genome sequencing technologies, predicting costs could drop to as low as $20 soon. The conversation shifts to the application of deep learning in biology, contrasting it with traditional machine learning methods previously used in the field.
